Clinical trial
Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme
NCT00359047 · CHU de Quebec-Universite Laval, Other · Unknown status
Key facts
| NCT number | NCT00359047 |
|---|---|
| Title | Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme |
| Official title | Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme |
| Lead sponsor | CHU de Quebec-Universite Laval, Other |
| Collaborators | Merck Frosst Canada Ltd. Industry Sanofi Procter and Gamble Amgen Eli Lilly and Company Novartis |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Behavioral |
| Interventions | Documentation, Video |
| Enrollment | 2,830 |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Dec 1, 2025 |
| First posted | Aug 1, 2006 |
| Last update posted | Nov 21, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: